Acceleron Pharma Inc.
TGF-BETA RECEPTOR TYPE II VARIANTS AND USES THEREOF

Last updated:

Abstract:

In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T.beta.RII polypeptide useful to selectively antagonize a T.beta.RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF.beta. associated disorders.

Status:
Application
Type:

Utility

Filling date:

24 Apr 2019

Issue date:

19 Sep 2019